SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

FOR IMMEDIATE RELEASE

SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics MUMBAI – September 22, 2020, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced the grant of an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.

Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg.

The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.

“ElepsiaTM XR can bring down the daily pill burden significantly and will be an alternative treatment option for patients suffering with epilepsy,” said Anil Raghavan, CEO of SPARC.

President of Tripoint, Steve Squashic said “We are very excited about the relationship with SPARC and look forward to bringing ElepsiaTM XR to patients in USA.”

About ElepsiaTM (Levetiracetam) XR 1000 mg/1500 mg tablet: ElepsiaTM XR is a novel product designed and approved by the USFDA as an extended release formulation of Levetiracetam 1000 mg/1500 mg, indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older, developed using SPARC’s WrapMatrixTM technology.